Display options
Cite
Heidari M, Bayani M, Bijani A, et al. Factors influencing therapeutic response to pegylated interferon plus ribavirin in the different genotypes of chronic hepatitis C. Caspian J Intern Med. 2014;5(4):219-22
Heidari, M., Bayani, M., Bijani, A., & Hasanjani Roushan, M. R. (2014). Factors influencing therapeutic response to pegylated interferon plus ribavirin in the different genotypes of chronic hepatitis C. Caspian journal of internal medicine, 5(4), 219-22.
Heidari, Mehdi, et al. "Factors influencing therapeutic response to pegylated interferon plus ribavirin in the different genotypes of chronic hepatitis C." Caspian journal of internal medicine vol. 5,4 (2014): 219-22.
Heidari M, Bayani M, Bijani A, Hasanjani Roushan MR. Factors influencing therapeutic response to pegylated interferon plus ribavirin in the different genotypes of chronic hepatitis C. Caspian J Intern Med. 2014;5(4):219-22. PMID: 25489433; PMCID: PMC4247485.
Copy Download .nbib Format: NLM
Share it on

Caspian J Intern Med. 2014;5(4):219-22.

Factors influencing therapeutic response to pegylated interferon plus ribavirin in the different genotypes of chronic hepatitis C.

Caspian journal of internal medicine

Mehdi Heidari, Masomeh Bayani, Ali Bijani, Mohammad Reza Hasanjani Roushan

Affiliations

  1. 1. Infectious Diseases and Tropical Medicine Research Center, Babol University of Medical Sciences, Babol, Iran.

PMID: 25489433 PMCID: PMC4247485

Abstract

BACKGROUND: Different factors like age, sex, route of infection, initial viral load, levels of liver function tests and genotypes may affect response to treatment in patients with chronic hepatitis C. The purpose of this study was to determine the role of these factors in the treatment of these patients.

METHODS: From 2004 to 2012, different genotypes of chronic HCV (Hepatitis C virus) patients in Babol, North of Iran who were treated with pegylated interferon plus ribavirin with standard doses (48 weeks for genotype 1, and 24 weeks for genotypes 2 and 3) were entered in the study. HCV RNA was measured during and after treatment based on genotype and protocol. The outcome measure was defined as sustained virological response (SVR) (negative HCV RNA after six months of therapy) was achieved. The data were collected and analyzed.

RESULTS: The mean age of the patients (61 males, 5 females) was 33.82±9.64 years. Twenty seven (40.9%), 37 (56.1%) and 2 (%3) were genotypes 1, 2 and 3, respectively. Twenty one (77.8%) with genotype 1, and 34 (91.9%) with genotype 3 achieved SVR (P=0.045). Fifty-five of 61 men (90.2%) and 2 out of 5 females (40%) achieved SVR (P=0.01). SVR was seen in 22 (88%) of 25 IV drug patients versus in 35 (85.4%) of the non-addict cases (p>0.05). There were no significant differences regarding age, viral load, and liver aminotransferase levels with treatment.

CONCLUSION: The results show that genotypes 2 and 3, and the male sex had better SVR. Further studies with large number of cases are recommended.

Keywords: Chronic hepatitis C; Genotype; IV drug abuser; Sex; Treatment; Virological response

References

  1. Korean J Hepatol. 2011 Sep;17 (3):220-5 - PubMed
  2. Gastroenterology. 2000 Nov;119(5):1385-96 - PubMed
  3. Hepatology. 2003 Sep;38(3):645-52 - PubMed
  4. N Engl J Med. 2006 Dec 7;355(23 ):2444-51 - PubMed
  5. Lancet. 2001 Sep 22;358(9286):958-65 - PubMed
  6. N Engl J Med. 2009 Jan 15;360(3):257-67 - PubMed
  7. Semin Liver Dis. 2011 Nov;31(4):331-9 - PubMed
  8. J Hepatol. 2014 Feb;60(2):392-420 - PubMed
  9. N Engl J Med. 2011 Jun 23;364(25):2429-38 - PubMed
  10. Gastroenterology. 2006 Jan;130(1):231-64; quiz 214-7 - PubMed
  11. Gastroenterology. 2000 Nov;119(5):1317-23 - PubMed
  12. N Engl J Med. 2013 May 16;368(20):1907-17 - PubMed
  13. East Mediterr Health J. 2011 Aug;17 (8):669-78 - PubMed

Publication Types